Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers.
Perez-Diaz-Del-Campo N, Riezu-Boj JI, Marin-Alejandre BA, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Milagro FI, Bugianesi E, Tur JA, Martinez JA, Abete I, Zulet MA. Perez-Diaz-Del-Campo N, et al. Among authors: bugianesi e. Panminerva Med. 2022 Dec;64(4):485-496. doi: 10.23736/S0031-0808.22.04590-6. Epub 2022 Apr 19. Panminerva Med. 2022. PMID: 35437302 Clinical Trial.
The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease.
Armandi A, Colombo G, Rosso C, Caviglia GP, Olivero A, Abate ML, Guariglia M, Perez Diaz Del Campo N, Castelnuovo G, Ribaldone DG, Saracco GM, Genazzani AA, Bugianesi E. Armandi A, et al. Among authors: bugianesi e. Int J Mol Sci. 2023 Jan 7;24(2):1172. doi: 10.3390/ijms24021172. Int J Mol Sci. 2023. PMID: 36674688 Free PMC article.
Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
Armandi A, Rosso C, Younes R, Leeming DJ, Karsdal MA, Caviglia GP, Pérez-Diaz-Del-Campo N, D'Amato D, Abdulle A, Nicolosi A, Castelnuovo G, Saracco GM, Ribaldone DG, Bugianesi E. Armandi A, et al. Among authors: bugianesi e. J Clin Med. 2023 Jan 13;12(2):650. doi: 10.3390/jcm12020650. J Clin Med. 2023. PMID: 36675579 Free PMC article.
Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
Castelnuovo G, Perez-Diaz-Del-Campo N, Guariglia M, Poggiolini I, Armandi A, Rosso C, Caviglia GP, Bugianesi E. Castelnuovo G, et al. Among authors: bugianesi e. Minerva Gastroenterol (Torino). 2023 Mar 9. doi: 10.23736/S2724-5985.23.03361-2. Online ahead of print. Minerva Gastroenterol (Torino). 2023. PMID: 36892817
Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease.
Armandi A, Caviglia GP, Abdulle A, Rosso C, Gjini K, Castelnuovo G, Guariglia M, Perez Diaz Del Campo N, D'Amato D, Ribaldone DG, Saracco GM, Bugianesi E. Armandi A, et al. Among authors: bugianesi e. Cancers (Basel). 2023 Mar 8;15(6):1659. doi: 10.3390/cancers15061659. Cancers (Basel). 2023. PMID: 36980543 Free PMC article.
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease.
Rosso C, Caviglia GP, Birolo G, Armandi A, Pennisi G, Pelusi S, Younes R, Liguori A, Perez-Diaz-Del-Campo N, Nicolosi A, Govaere O, Castelnuovo G, Olivero A, Abate ML, Ribaldone DG, Fariselli P, Valenti L, Miele L, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. Rosso C, et al. Among authors: bugianesi e. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3314-3321.e3. doi: 10.1016/j.cgh.2023.04.024. Epub 2023 May 4. Clin Gastroenterol Hepatol. 2023. PMID: 37149016
321 results